Articles

In partnership with the University of Pittsburgh, ElevateBio will open its next manufacturing center in the city.

ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center

Roche’s acquisition of Good Therapeutics grants them rights to the company's conditionally activated PD-1-regulated IL-2 program.

Roche to Acquire Good Therapeutics for $250 Million

SIRIO is enhancing its strategy for small and medium nutrition brands as Lonza’s Sara Lesina joins as GM in Europe.

SIRIO Enhances Company Strategy with Addition of Lonza’s Sara Lesina

Lynparza has been approved in Great Britain as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer.

Lynparza Approved in Great Britain

Sanofi’s Xenpozyme (olipudase alfa-rpcp) is now the only approved treatment for acid sphingomyelinase deficiency.

FDA Approves Novel ASMD Treatment from Sanofi

Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.

Lonza and Touchlight Enter mRNA Collaboration

The patent applications are for programs concerning lupus, idiopathic pulmonary fibrosis, and chronic kidney disease.

Aria Pharmaceuticals Files Applications for Six Provisional Patents

Alasdair Leckie is operations director at Rephine Ltd, a firm of deeply experienced GMP auditors which proactively help pharmaceutical companies around the world with their supply-chain quality assurance. Alasdair has been with Rephine for nine years and has a Bachelor’s Degree in Chinese and Economics from SOAS University of London.

A new survey has demonstrated that remote audits, brought to the fore thanks to COVID-19, are not necessarily a preferred option for clients. 

Will Remote Pharma GMP Auditing Endure Post-Pandemic?

Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.

Hovione Expands its Continuous Manufacturing Offering and Services

Novo Nordisk’s $1.1 billion acquisition of Forma Therapeutics is intended to expand its sickle cell and rare blood disorder portfolio.

News